SSShrijal S. Shah

Shrijal S. Shah

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shrijal S. Shah has a total of 33 co-authors. Here are the top co-authors by number of shared publications:

  • David J. Friedman

    Renal Division, Beth Israel Deaconess Medical Center, Boston, USA

    4 shared publications
  • Herbert Lannon

    CytoTronics Inc., Boston, USA

    2 shared publications
  • Leny Dias

    Division of Nephrology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA

    2 shared publications
  • Martin R. Pollak

    Division of Nephrology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA

    2 shared publications
  • Seth L. Alper

    Division of Nephrology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA

    2 shared publications
  • Althea Bock-Hughes

    Ben May Department for Cancer Research, University of Chicago

    1 shared publication

Latest Publications

  • Open Access

    Recessive, gain-of-function toxicity in an APOL1 BAC transgenic mouse model mirrors human APOL1 kidney disease

    by Gizelle M. McCarthy, Angelo Blasio, Olivia G. Donovan, Lena B. Schaller, Althea Bock-Hughes, Jose M. Magraner, Jung Hee Suh, Calum F. Tattersfield, Isaac E. Stillman, Shrijal S. Shah, et al.

    People of recent sub-Saharan African ancestry develop kidney failure much more frequently than other groups. A large fraction of this disparity is due to two coding sequence variants in the APOL1 gene. Inheriting two copies of these APOL1 risk variants, known as G1 and G2, causes high rates of focal segmental glomerulosclerosis (FSGS), HIV-associated nephropathy and hypertension-associated end-stage kidney disease. Disease risk follows a recessive mode of inheritance, which is puzzling given the considerable data that G1 and G2 are toxic gain-of-function variants. We developed coisogenic bacterial artificial chromosome (BAC) transgenic mice harboring either the wild-type (G0), G1 or G2 forms of human APOL1. Expression of interferon gamma (IFN-γ) via plasmid tail vein injection results in upregulation of APOL1 protein levels together with robust induction of heavy proteinuria and glomerulosclerosis in G1/G1 and G2/G2 but not G0/G0 mice. The disease phenotype was greater in G2/G2 mice. Neither heterozygous (G1/G0 or G2/G0) risk variant mice nor hemizygous (G1/−, G2/−) mice had significant kidney injury in response to IFN-γ, although the heterozygous mice had a greater proteinuric response than the hemizygous mice, suggesting that the lack of significant disease in humans heterozygous for G1 or G2 is not due to G0 rescue of G1 or G2 toxicity. Studies using additional mice (multicopy G2 and a non-isogenic G0 mouse) supported the notion that disease is largely a function of the level of risk variant APOL1 expression. Together, these findings shed light on the recessive nature of APOL1-nephropathy and present an important model for future studies.


  • Faculty Opinions recommendation of Discriminating α-synuclein strains in Parkinson's disease and multiple system atrophy.

    by David Friedman, Shrijal Shah

    Parkinson’s disease (PD) and multiple system atrophy (MSA) are degenerative diseases of the nervous system that can be caused by aberrant alpha synuclein behavior. They present with similar symptoms at early stages and often require waiting to see how the disease progresses to make a specific diagnosis. This study aims to understand how a single protein - alpha synuclein - can lead to the development of these two distinct disease phenotypes. Using cerebrospinal fluid and brain lysates as seeding material to catalyze the aggregation of alpha synuclein monomers, the authors show that the resulting alpha synuclein aggregates exist in different confirmations in patients with PD versus MSA. This protein misfolding cyclic aggregation (PMCA) assay was able to distinguish patients with PD and MSA with high sensitivity and specificity and could have direct implications on development of new diagnostic tests. The authors show that alpha synuclein aggregates are biochemically, structurally, and biologically distinct in PD and MSA by proteolytic digestions, secondary and quaternary structural analysis, and cytotoxicity assays. Determining the microenvironment that influences the formation of either type of alpha synuclein strains will further our understanding of these synucleinopathies. This line of inquiry could be applied to other amyloid diseases across a range of organ systems. Hereditary renal amyloid diseases are difficult to diagnose and require biopsy. Using non-invasive biological materials like blood or urine as starting seed material to make a predictive diagnosis could be very useful in the future.​

  • Apolipoprotein L1 (APOL1) risk variant toxicity depends on the haplotype background

    by Herbert Lannon, Shrijal S. Shah, Leny Dias, Daniel Blackler, Seth L. Alper, Martin R. Pollak, David J. Friedman


  • Open Access

    Faculty Opinions recommendation of Mitochondrial permeability uncouples elevated autophagy and lifespan extension.

    by David Friedman, Shrijal Shah

    Autophagy is a process for the degradation and recycling of cellular components important for metabolism under stress, for removal of protein aggregates, and for defense against pathogens. Using several different experimental systems, the authors show that autophagy, which is generally thought to be beneficial for longevity, becomes detrimental when the mitochondrial permeability transition pore (mPTP) is open. Functional mTORC2 is necessary for modulating abundance of outer mitochondrial membrane protein VDAC1. In this noteworthy study, toxic accumulation of VDAC1 in mTORC2 mutant worms led to prolonged opening of the mPTP, a non-specific pore that allows free passage of molecules <1.5kDa, rendering mitochondria dysfunctional and inducing autophagy. But instead of being protective, autophagy had an adverse effect on worm lifespan due to excessive clearance of fragmented mitochondria (“mitophagy”). Inhibiting autophagy or mPTP opening restored normal lifespan. mPTP activity appears to modulate the effects of autophagy, with low mPTP activity a necessity for the favorable effects of autophagy. A deeper understanding of the relationship between mPTP and autophagy might lead to new insights into healthy aging as well as a variety of kidney-related phenotypes dependent on autophagy, such as glomerular integrity and ischemia/reperfusion injury.

  • APOL1 Kidney Risk Variants Induce Cell Death via Mitochondrial Translocation and Opening of the Mitochondrial Permeability Transition Pore

    by Shrijal S. Shah, Herbert Lannon, Leny Dias, Jia-Yue Zhang, Seth L. Alper, Martin R. Pollak, David J. Friedman

    Significance Statement: Some variants in APOL1 are associated with high CKD rates in African Americans, but the molecular mechanism of disease remains elusive. Previous studies demonstrated that expression of APOL1 risk variants is associated with mitochondrial dysfunction. In this study, the authors show that import of APOL1 protein into mitochondria is essential for risk variant–mediated cytotoxicity, and map the APOL1 import pathway. They found that whereas APOL1 is mostly monomeric, risk variant APOL1 can form large oligomers and cause opening of the mitochondrial permeability transition pore, ultimately leading to cell death. This difference in propensity of different variants to oligomerize could help explain APOL1 risk variants’ gain-of-function biology despite a recessive mode of inheritance. Understanding APOL1 trafficking and interactions could help inform new therapeutic approaches. Background: Genetic Variants in Apolipoprotein L1 (APOL1) are associated with large increases in CKD rates among African Americans. Experiments in cell and mouse models suggest that these risk-related polymorphisms are toxic gain-of-function variants that cause kidney dysfunction, following a recessive mode of inheritance. Recent data in trypanosomes and in human cells indicate that such variants may cause toxicity through their effects on mitochondria. Methods: To examine the molecular mechanisms underlying APOL1 risk variant–induced mitochondrial dysfunction, we generated tetracycline-inducible HEK293 T-REx cells stably expressing the APOL1 nonrisk G0 variant or APOL1 risk variants. Using these cells, we mapped the molecular pathway from mitochondrial import of APOL1 protein to APOL1-induced cell death with small interfering RNA knockdowns, pharmacologic inhibitors, blue native PAGE, mass spectrometry, and assessment of mitochondrial permeability transition pore function. Results: We found that the APOL1 G0 and risk variant proteins shared the same import pathway into the mitochondrial matrix. Once inside, G0 remained monomeric, whereas risk variant proteins were prone to forming higher-order oligomers. Both nonrisk G0 and risk variant proteins bound components of the mitochondrial permeability transition pore, but only risk variant proteins activated pore opening. Blocking mitochondrial import of APOL1 risk variants largely eliminated oligomer formation and also rescued toxicity. Conclusions: Our study illuminates important differences in the molecular behavior of APOL1 nonrisk and risk variants, and our observations suggest a mechanism that may explain the very different functional effects of these variants, despite the lack of consistently observed differences in trafficking patterns, intracellular localization, or binding partners. Variant-dependent differences in oligomerization pattern may underlie APOL1’s recessive, gain-of-function biology.


  • Androgen Receptor Is the Key Transcriptional Mediator of the Tumor Suppressor SPOP in Prostate Cancer

    by Chuandong Geng, Kimal Rajapakshe, Shrijal S. Shah, John Shou, Vijay Kumar Eedunuri, Christopher Foley, Warren Fiskus, Mahitha Rajendran, Sue Anne Chew, Martin Zimmermann, et al.

    Somatic missense mutations in the substrate-binding pocket of the E3 ubiquitin ligase adaptor SPOP are present in up to 15% of human prostate adenocarcinomas, but are rare in other malignancies, suggesting a prostate-specific mechanism of action. SPOP promotes ubiquitination and degradation of several protein substrates, including the androgen receptor (AR) coactivator SRC-3. However, the relative contributions that SPOP substrates may make to the pathophysiology of SPOP-mutant (mt) prostate adenocarcinomas are unknown. Using an unbiased bioinformatics approach, we determined that the gene expression profile of prostate adenocarcinoma cells engineered to express mt-SPOP overlaps greatly with the gene signature of both SRC-3 and AR transcriptional output, with a stronger similarity to AR than SRC-3. This finding suggests that in addition to its SRC-3–mediated effects, SPOP also exerts SRC-3–independent effects that are AR-mediated. Indeed, we found that wild-type (wt) but not prostate adenocarcinoma–associated mutants of SPOP promoted AR ubiquitination and degradation, acting directly through a SPOP-binding motif in the hinge region of AR. In support of these results, tumor xenografts composed of prostate adenocarcinoma cells expressing mt-SPOP exhibited higher AR protein levels and grew faster than tumors composed of prostate adenocarcinoma cells expressing wt-SPOP. Furthermore, genetic ablation of SPOP was sufficient to increase AR protein levels in mouse prostate. Examination of public human prostate adenocarcinoma datasets confirmed a strong link between transcriptomic profiles of mt-SPOP and AR. Overall, our studies highlight the AR axis as the key transcriptional output of SPOP in prostate adenocarcinoma and provide an explanation for the prostate-specific tumor suppressor role of wt-SPOP. Cancer Res; 74(19); 5631–43. ©2014 AACR.